The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Laurie Sehn, MD, BC Cancer Agency, Vancouver, Canada, Carmelo Carlo Stella, MD, PhD, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan Italy, and David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, share some insights into novel therapies in non-Hodgkin lymphoma (NHL), drawing focus on the role of antibody-drug conjugates (ADCs). The experts discuss updates on the use of several ADCs, including brentuximab vedotin, loncastuximab tesirine, polatuzumab vedotin, and camidanlumab tesirine, and where these agents fit in the treatment landscape.
The post iwNHL Session V: novel therapies in NHL – the role of ADCs appeared first on VJHemOnc.
